spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Healthcare Industry News:  electron-beam 

Devices Oncology Surgery

 News Release - March 12, 2009

China's Shanghai Ruijin Chooses the Mobetron for Advanced Cancer Care

SUNNYVALE, Calif.--(HSMN NewsFeed)--IntraOp Medical Corporation (OTCBB: IOPM ), a provider of intraoperative electron-beam radiation therapy (IOERT) solutions for the treatment and eradication of cancer, announced today an order for its Mobetron device from the Shanghai Ruijin Hospital in Shanghai, China.

IntraOp’s Mobetron is a mobile technology that delivers IOERT to a tumor site during cancer surgery. The Mobetron enables radiation and surgical oncologists to pinpoint the optimal site for radiation and deliver an effective dose during the procedure. Since the Mobetron is a mobile, self-shielded device, doctors will be able to move the Mobetron among different operating rooms to more efficiently treat a greater number of patients. Shanghai Ruijin will use the Mobetron to treat many forms of cancer, including breast, colorectal, sarcoma, and lung cancers.

This marks the fourth Mobetron installed in China. In the six months since installing the first Mobetron device and beginning treatments, oncologists in China have had notable success using IOERT for cancer therapy, inspiring other centers to follow suit. Two institutions in Beijing have been using the Mobetron since September of 2008 and have extremely high utilization rates, reflecting the Chinese doctors’ commitment and enthusiasm for IOERT as an emerging standard-of-care for surgeries requiring tumor resection.

Prof. King, director of the radiation Oncology Department, said, “The Mobetron will augment the surgical and radiotherapy department for Ruijin. This will allow the oncologists there to quickly and effectively treat a larger number of patients, while reducing tumor recurrences and saving lives.”

IntraOp CEO John Powers added, “We continue to be optimistic about the rapid adoption of the Mobetron technology and IOERT in China. This is the fourth order we’ve received in only 18 months. It is clear that IOERT is having an immediate impact on the delivery of radiation therapy in China.”

About IntraOp

IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer intraoperative radiation therapy safely and effectively – for all cancer patients. The company’s flagship product, the Mobetron, is the first fully portable, self-shielding intraoperative electron radiation therapy device designed for use in any operating room. Key Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals, from university research centers to specialized cancer clinics in North America, Europe and Asia, use the Mobetron as a vital part of their comprehensive cancer program.

For more information about IntraOp Medical and the Mobetron, please visit: www.intraopmedical.com

Source: IntraOp Medical

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

Search: IntraOp Medical 
Search: Mobetron 
Search: intraoperative radiation therapy 
Search: radiotherapy 
Healthcare Industry NewsFeed  


FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.